| Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial TU Marron, MI Fiel, P Hamon, N Fiaschi, E Kim, SC Ward, Z Zhao, J Kim, ... The Lancet Gastroenterology & Hepatology 7 (3), 219-229, 2022 | 103 | 2022 |
| Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma A Magen, P Hamon, N Fiaschi, BY Soong, MD Park, R Mattiuz, E Humblin, ... Nature medicine 29 (6), 1389-1399, 2023 | 68 | 2023 |
| Supporting informed decision-making about vaccination: an analysis of two official websites M Vivion, C Hennequin, P Verger, E Dubé Public health 178, 112-119, 2020 | 29 | 2020 |
| An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis NM LaMarche, S Hegde, MD Park, BB Maier, L Troncoso, J Le Berichel, ... Nature 625 (7993), 166-174, 2024 | 10 | 2024 |
| Intratumoral mregDC and CXCL13 T helper niches enable local differentiation of CD8 T cells following PD-1 blockade A Magen, P Hamon, N Fiaschi, L Troncoso, E Humblin, D D’souza, ... BioRxiv, 2022.06. 22.497216, 2022 | 9 | 2022 |
| Hapten-specific T cell-mediated skin inflammation: Flow cytometry analysis of mouse skin inflammatory infiltrate N Bouladoux, C Hennequin, C Malosse, B Malissen, Y Belkaid, S Henri Inflammation: Methods and Protocols, 21-36, 2017 | 5 | 2017 |
| A phase 1b/2 trial of dupilumab given in conjunction with PD-(L) 1 blockade in the treatment of relapsed/refractory metastatic NSCLC. BG Fitzgerald, TU Marron, N Hall, D O'Grady, N LaMarche, C Hennequin, ... Journal of Clinical Oncology 40 (16_suppl), TPS9139-TPS9139, 2022 | 2 | 2022 |
| 629 Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma N Venturini, T Marron, M Casanova-Acebes, J Mandeli, D Doroshow, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| P2. 12-05 Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes with PD-L1 Blockade to Reverse Type-2Mediated Immunosuppression TU Marron, B Maier, NM LaMarche, S Hegde, M Belabed, R Mattiuz, ... Journal of Thoracic Oncology 17 (9), S153-S154, 2022 | 1 | 2022 |
| L’actualité immunologique sous l’œil critique des doctorants B Diallo, C Hennequin, J Jouniaux, A Lassalle-Laxenaire, MLS Sola, ... médecine/sciences 31, 139-42, 2015 | 1 | 2015 |
| 170P Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: A window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 … NJ Venturini, P Hamon, S Ward, MI Fiel, MB Beasley, E Kim, ... Immuno-Oncology and Technology 20, 2023 | | 2023 |
| 650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer N Lucas, N Venturini, S Hegde, R Mattiuz, C Hennequin, J Le Berichel, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Abstract CT199: Rescuing response to ICI by blocking the type-2 immune axis in patients with NSCLC progressing on immunotherapy: A phase 1b/2 trial of dupilumab administered … TU Marron, NM LaMarche, MD Park, S Hegde, B Fitzgerald, C Hennequin, ... Cancer Research 83 (8_Supplement), CT199-CT199, 2023 | | 2023 |
| NEOADJUVANT NIVOLUMAB COMBINED WITH CCR2/5 INHIBITOR OR ANTI-IL-8 ANTIBODY IN NON-SMALL CELL LUNG CANCER AND HEPATOCELLULAR CARCINOMA N Venturini, T Marron, M Casanova-Acebes, J Mandeli, D Doroshow, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 10, A661-A661, 2022 | | 2022 |
| 629 Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma N Venturini, T Marron, M Casanova-Acebes, J Mandeli, D Doroshow, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Parents and health professionals’ opinions on information tools on mandatory childhood vaccines CH Hennequin, C Vergelys, L Chauvet, SC Cortaredona, E Dube, ... European Journal of Public Health 29 (Supplement_4), ckz187. 103, 2019 | | 2019 |
